Gene: NRAS ×
Source: CURATED ×
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs121913250
rs121913250
NRAS
T 0.720 CausalMutation CLINVAR Distinct sets of genetic alterations in melanoma. 16291983

2005
dbSNP: rs121434595
rs121434595
NRAS
G 0.700 CausalMutation CLINVAR Distinct sets of genetic alterations in melanoma. 16291983

2005
dbSNP: rs121434595
rs121434595
NRAS
A 0.700 CausalMutation CLINVAR Distinct sets of genetic alterations in melanoma. 16291983

2005
dbSNP: rs121434596
rs121434596
NRAS
A 0.700 CausalMutation CLINVAR Distinct sets of genetic alterations in melanoma. 16291983

2005
dbSNP: rs121434596
rs121434596
NRAS
G 0.700 CausalMutation CLINVAR Distinct sets of genetic alterations in melanoma. 16291983

2005
dbSNP: rs121434596
rs121434596
NRAS
T 0.700 CausalMutation CLINVAR Distinct sets of genetic alterations in melanoma. 16291983

2005
dbSNP: rs121913255
rs121913255
NRAS
G 0.700 CausalMutation CLINVAR Distinct sets of genetic alterations in melanoma. 16291983

2005
dbSNP: rs121913255
rs121913255
NRAS
A 0.700 CausalMutation CLINVAR Distinct sets of genetic alterations in melanoma. 16291983

2005
dbSNP: rs1057519695
rs1057519695
NRAS
CA 0.800 CausalMutation CLINVAR First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. 22761467

2012
dbSNP: rs1057519695
rs1057519695
NRAS
CC 0.800 CausalMutation CLINVAR First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. 22761467

2012
dbSNP: rs11554290
rs11554290
NRAS
A 0.800 CausalMutation CLINVAR First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. 22761467

2012
dbSNP: rs11554290
rs11554290
NRAS
G 0.800 CausalMutation CLINVAR First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. 22761467

2012
dbSNP: rs11554290
rs11554290
NRAS
C 0.800 CausalMutation CLINVAR First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. 22761467

2012
dbSNP: rs121913254
rs121913254
NRAS
C 0.780 CausalMutation CLINVAR First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. 22761467

2012
dbSNP: rs121913255
rs121913255
NRAS
A 0.700 CausalMutation CLINVAR First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. 22761467

2012
dbSNP: rs121913255
rs121913255
NRAS
G 0.700 CausalMutation CLINVAR First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. 22761467

2012
dbSNP: rs1057519695
rs1057519695
NRAS
CA 0.800 CausalMutation CLINVAR Furthermore, PLX4032 increased the rate of proliferation of growth factor-dependent NRAS Q61L mutant primary melanoma cells, reduced cell adherence and increased mobility of cells from advanced lesions. 20149136

2010
dbSNP: rs11554290
rs11554290
NRAS
A 0.800 CausalMutation CLINVAR Furthermore, PLX4032 increased the rate of proliferation of growth factor-dependent NRAS Q61L mutant primary melanoma cells, reduced cell adherence and increased mobility of cells from advanced lesions. 20149136

2010
dbSNP: rs1057519695
rs1057519695
NRAS
CC 0.800 CausalMutation CLINVAR Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. 23538902

2013
dbSNP: rs1057519695
rs1057519695
NRAS
CA 0.800 CausalMutation CLINVAR Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. 23538902

2013
dbSNP: rs11554290
rs11554290
NRAS
C 0.800 CausalMutation CLINVAR Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. 23538902

2013
dbSNP: rs11554290
rs11554290
NRAS
A 0.800 CausalMutation CLINVAR Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. 23538902

2013
dbSNP: rs11554290
rs11554290
NRAS
G 0.800 CausalMutation CLINVAR Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. 23538902

2013
dbSNP: rs121913254
rs121913254
NRAS
C 0.780 CausalMutation CLINVAR Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. 23538902

2013
dbSNP: rs121913255
rs121913255
NRAS
G 0.700 CausalMutation CLINVAR Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. 23538902

2013